Management of anemia in patients with congestive heart failure

被引：39
|
作者：
Goodnough, Lawrence Tim
Comin-Colet, Josep [1 ,2 ]
Leal-Noval, Santiago [3 ]
Ozawa, Sherri [4 ]
Takere, Jacqueline [5 ]
Henry, David [6 ]
Javidroozi, Mazyar [7 ]
Hohmuth, Benjamin [8 ]
Bisbe, Elvira [9 ,10 ]
Gross, Irwin [11 ]
Shander, Aryeh [12 ,13 ]
机构：
[1] Bellvitge Univ Hosp, Heart Failure Program, Dept Cardiol, Barcelona, Spain
[2] Biomed Res Inst, Barcelona, Spain
[3] Univ Hosp Virgen delRocio, Crit Care Div, Dept Crit Care, Avda Manuel Siurot S-N, Seville, Spain
[4] Englewood Hosp & Med Ctr, Inst Patient Blood Management & Bloodless Med & S, Englewood, NJ USA
[5] ASHP Pharm Residency Program, Dept Pharm, Investigat Drug Serv, Pharm & Therapeutics Oncol Serv, Englewood, NJ USA
[6] Penn Hosp, Abramson Canc Ctr, Penn Hematol Oncol, Dept Med, Philadelphia, PA 19107 USA
[7] Englewood Hosp & Med Ctr, Dept Anesthesiol, Englewood, NJ USA
[8] Temple Univ, Dept Hosp Med, Sch Med, Representing Soc Hosp Med, Philadelphia, PA 19122 USA
[9] Hosp Univ Mar, Dept Anaesthesiol & Reanimat, Barcelona, Spain
[10] Hosp Mar Med Res Inst, IMIM Coordinat Anemia Working Grp Espana, Perioperat Med Res Grp, Barcelona, Spain
[11] Accumen LLC, San Diego, CA USA
[12] Icahn Sch Med, Med & Surg, New York, NY USA
[13] Englewood Hosp & Med Ctr, TeamHlth Res Inst, Dept Anesthesiol Crit Care Pain & Hyperbar Med, Englewood, NJ USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2017年 / 92卷 / 01期
关键词：
REDUCED EJECTION FRACTION; QUALITY-OF-LIFE; INTRAVENOUS FERRIC CARBOXYMALTOSE; IRON-DEFICIENCY; AMERICAN-COLLEGE; CO-MORBIDITIES; TASK-FORCE; NEW-ONSET; ASSOCIATION; IMPACT;
D O I：
10.1002/ajh.24595
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码：88 / 93
页数：6
相关论文
共 50 条
12345